183 Results
Sort By:
Published on June 5, 2024
The first patient has received a personalized vaccine in a clinical trial as part of NHS England’s new Cancer Vaccine Launch Pad. The plan is that thousands of patients in England will gain access to personalized cancer vaccine trials through the new “matchmaking” service for patients and drug developers. Thirty…
Published on May 1, 2024
Researchers at the University of Florida report they have developed an mRNA cancer vaccine that quickly reprograms the immune system to attack glioblastoma in a first-ever human clinical trial of four adult patients. Their results published in Cell mirror those from preclinical mouse studies, and from a newly reported trial…
Published on September 13, 2023
OSE Immunotherapeutics SA, a pioneering biotech company in the field of immuno-oncology and immuno-inflammation, has announced hopeful results from its 2:1 randomized phase III clinical trial, known as Atalante-1, involving the T-cell epitope cancer vaccine Tedopi®. The trial focused on patients with advanced or metastatic non-small cell lung cancer (NSCLC)…
Published on August 21, 2023
Moderna will partner with Chinese biotech CARsgen to co-develop a combined CAR T-cell and mRNA cancer vaccine therapy. The collaboration aims to combine Moderna’s Claudin18.2 mRNA cancer vaccine with CARsgen’s investigational Claudin18.2 autologous CAR T-cell product candidate (CT041) to test efficacy for targeting hard to treat cancers. Claudin 18.2 is…
Published on May 4, 2023
An alliance between the American Lung Association (ALA) and Gateway for Cancer Research, a nonprofit organization funding early phase clinical trials, will provide $678,000 of funding for a five-year vaccine trial targeting small cell lung cancer (SCLC). The trial, which began enrolling patients last spring is led by Jeffrey Ward,…
Published on February 1, 2023
Researchers from the International Institute for Nanotechnology (IIN) at Northwestern University have combined chemistry and nanotechnology to change the structural location of adjuvants and antigens on and within a nanoscale cancer vaccine to boost potency and performance. Their method was published recently in Nature Biomedical Engineering. “Cancer vaccines must activate multiple…
Published on August 17, 2022
Scientists demonstrate an endogenously lymph node-targeting lipid nanoparticle (LNP), without the modification of any active targeting ligands, for developing an mRNA cancer vaccine. This method of targeting cancer in mice eliminated tumors and even prevented their recurrence. This work is published in Proceedings of the National Academy of Sciences. “What…
Published on September 17, 2021
New research from investigators at MIT may help guide vaccine developers to decide which proteins to include in new vaccines against cancer. Cancer cells display unique mutated proteins called neoantigens on their surfaces. Fragments of certain neoantigens when injected into the body can stimulate the body’s immune system to annihilate…
Published on March 26, 2021
Over the last year mRNA vaccine development to combat COVID-19 has happened extremely quickly, but whether these scientific advances can have a positive impact on the development of cancer vaccines remains to be seen. At the beginning of 2020, no mRNA drugs or vaccines were on the market. Since the…
Published on October 2, 2019
Scientists at Arizona State University’s Biodesign Institute now report on the identification of more than 200,000 cancer neoantigens, which could feasibly lead to the development of broad-spectrum cancer vaccines, as well as tumor type-specific treatments or patient-personalized vaccines. “In a cancer cell, it turns out that all levels of information…
Published on April 8, 2024
Researchers from the Memorial Sloan Kettering Cancer Center (MSKCC) have shown that an experimental investigational mRNA-based vaccine candidate shows potential to stimulate the immune system which may reduce the risk of pancreatic cancer returning after surgery. In new results from a Phase I trial, the candidate, autogene cevumeran, activated immune…
Published on February 7, 2024
Colorectal and pancreatic cancers—the second and third leading causes of cancer death, respectively—often have mutations in the KRAS protein. Now, a new vaccine that targets KRAS has shown encouraging early results as a potential off-the-shelf treatment for patients with pancreatic cancer or colorectal cancer, according to a study co-led by…
Published on January 9, 2024
An experimental cancer vaccine developed by Elicio Therapeutics to target tumors with KRAS mutations has achieved good results in a Phase I trial in patients with residual pancreatic and colorectal cancer following earlier treatment. As reported in Nature Medicine, the majority of patients in the study (84%) had a T…
Published on September 22, 2023
A small clinical trial conducted by investigators at Ludwig Cancer Research has shown that a treatment regimen for advanced ovarian cancer patients by combining adoptive T cell therapy (ACT) with a personalized cancer vaccine doubled overall survival time in patients. The research, detailed Thursday in Nature Cancer, was led by…
Published on January 12, 2023
The American Cancer Society (ACS) released today their annual report on cancer facts and trends, Cancer Statistics, 2023, showing overall cancer mortality has declined by 33% in the last 30 years, which translates to roughly 3.8 million deaths that were averted. The report also estimates that in the coming year,…